|Chemical and physical data|
|Molar mass||356.47 g/mol|
|3D model (Jmol)||Interactive image|
NNE1 (also known as NNEI, MN-24 and AM-6527) is an indole-based synthetic cannabinoid, representing a molecular hybrid of APICA and JWH-018. It was invented by Abbott and has a CB1 receptor pEC50 of 8.9 (i.e. EC50 of approximately 1nM) with around 80x selectivity over the related CB2 receptor. It is suspected that metabolic hydrolysis of the amide group of NNE1 may release 1-naphthylamine, a known carcinogen, given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, and NNE1 was banned in New Zealand in 2012 as a temporary class drug to stop it being used as an ingredient in then-legal synthetic cannabis products. NNE1 was subsequently found to be responsible for the death of a man in Japan in 2014.
- Nahoko Uchiyama; et al. (October 2014). "Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products". Forensic Science International. 243: 1–13. doi:10.1016/j.forsciint.2014.03.013. PMID 24769262.
- Antoni R. Blaazer; et al. (October 2011). "Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: Design, synthesis, structure–activity relationships, physicochemical properties and biological activity". European Journal of Medicinal Chemistry. 46 (10): 5086–5098. doi:10.1016/j.ejmech.2011.08.021. PMID 21885167.
- New Zealand Government Gazette, Notice Number 7051, 1 November 2012
- Chizuko Sasaki; et al. (January 2015). "A case of death caused by abuse of a synthetic cannabinoid N -1-naphthalenyl-1-pentyl-1H -indole-3-carboxamide". Forensic Toxicology. 33 (1): 165–169. doi:10.1007/s11419-014-0246-5.